eISSN: 2345-4202  
J Nephropharmacol. 2017;6(2):68-73.


Evaluation of the management of anemia in hemodialysis patients in Lebanon

Marwan Akel 1,2 * , Kholoud Shamas 1, Fouad Sakr 1, Mariam Dabbous 1, Jihan Safwan 1, Michelle Cherfan 1,3, Mohamad Iskandarani 1

1 School of Pharmacy, Lebanese International University, Museitbeh, Beirut, Lebanon
2 Universite Paul Sabatier, Toulouse, France
3 Universite Paris 13, Paris, France


Introduction: Chronic kidney disease (CKD) patients suffer anemia as one of the major complications. Optimal therapy involves the administration and response monitoring of erythropoiesis-stimulating agents and iron therapy.
Objectives: The purpose was to assess the adherence of anemia management in end-stage renal disease to Kidney Disease Outcomes Quality Initiative (KDOQI) recommendations. This study evaluated the impact of iron status on hemoglobin (Hb) levels, and its association with morbidity.
Patients and Methods: A prospective, multicenter, observational investigation was conducted at two hemodialysis (HD) centers over 6 months between 2013 and 2014. HD patients who aged more than 18 years without any history of active or chronic infection or cancer were enrolled. A total of 182 HD patients were included in the study.
Results: The included patients had a mean age of 57.28 years and mean Hb level of 10.29 ± 1.44 g/dL. A significant difference was noted between the prescribed and recommended doses of erythropoietin (EPO), along with that between prescribed and taken doses of EPO (P < 0.05). A significant difference was noted between the prescribed and taken iron doses (P < 0.05) in all months except December and April reflecting the association between the increase in Hb and adequate iron levels. Data on hospitalization was available for 78 individuals where Hb level was significantly lower in hospitalized versus non-hospitalized ones (9.92 versus 10.74 g/dL, P = 0.046).
Conclusion: Anemia management in HD patients depends on the adherence to the KDOQI recommendations for EPO dosing and iron status management. This sheds light on the need for the implementation of strict guidelines and clinical pharmacists’ involvement in HD units.
Implication for health policy/practice/research/medical education:
Adherence to the KDOQI recommendations for EPO dosing and managing iron status ameliorates anemia control in hemodialysis subjects. This highlights the necessity for strict implementation of guidelines and the involvement of a clinical pharmacist in hemodialysis units.
Please cite this paper as: Akel M, Shamas K, Sakr F, Dabbous M, Safwan J, Cherfan M, et al. Evaluation of the management of anemia in hemodialysis patients in Lebanon. J Nephropharmacol. 2017;6(2):68-73. DOI: 10.15171/npj.2017.07.
First name
Last name
Email address
Security code

Submitted: 14 Jan 2017

Accepted: 18 Mar 2017
First published online: 12 Apr 2017
EndNote EndNote

(Enw Format - Win & Mac)

BibTeX BibTeX

(Bib Format - Win & Mac)

Bookends Bookends

(Ris Format - Mac only)

EasyBib EasyBib

(Ris Format - Win & Mac)

Medlars Medlars

(Txt Format - Win & Mac)

Mendeley Web Mendeley Web
Mendeley Mendeley

(Ris Format - Win & Mac)

Papers Papers

(Ris Format - Win & Mac)

ProCite ProCite

(Ris Format - Win & Mac)

Reference Manager Reference Manager

(Ris Format - Win only)

Refworks Refworks

(Refworks Format - Win & Mac)

Zotero Zotero

(Ris Format - FireFox Plugin)

Abstract Page Views: 1413
PDF Downloads: 3543
Full Text Views: 0